AUTL
Income statement / Annual
Last year (2023), Autolus Therapeutics plc's total revenue was $1.70 M,
a decrease of 72.59% from the previous year.
In 2023, Autolus Therapeutics plc's net income was -$208.38 M.
See Autolus Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
09/30/2018 |
09/30/2017 |
09/30/2016 |
09/30/2015 |
| Operating Revenue |
$1.70 M
|
$6.19 M
|
$2.33 M
|
$242,000.00
|
$2.91 M
|
$1.05 M
|
$1.69 M
|
$1.21 M
|
$94,112.00
|
| Cost of Revenue |
$6.57 M |
$137.22 M |
$128.65 M |
$134.89 M |
$4.61 M |
$48.30 M |
$1.01 M |
$478,000.00 |
$0.00 |
| Gross Profit |
-$4.87 M |
-$131.03 M |
-$126.32 M |
-$134.65 M |
-$1.70 M |
-$47.25 M |
$684,001.00 |
$734,000.00 |
$94,112.00 |
| Gross Profit Ratio |
-2.87 |
-21.15 |
-54.22 |
-556.39 |
-0.59 |
-45.2 |
0.4 |
0.61 |
1 |
| Research and Development
Expenses |
$149.98 M
|
$141.99 M
|
$134.79 M
|
$134.89 M
|
$105.42 M
|
$24.64 M
|
$16.01 M
|
$10.44 M
|
$2.17 M
|
| General & Administrative
Expenses |
$45.65 M
|
$31.90 M
|
$31.87 M
|
$34.97 M
|
$39.45 M
|
$16.85 M
|
$9.10 M
|
$5.15 M
|
$6.04 M
|
| Selling & Marketing
Expenses |
$1.10 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$46.75 M
|
$31.90 M
|
$31.87 M
|
$34.97 M
|
$39.45 M
|
$16.85 M
|
$9.10 M
|
$5.15 M
|
$6.04 M
|
| Other Expenses |
$0.00 |
-$166,000.00 |
-$145,000.00 |
-$1.47 M |
$4.51 M |
$3.97 M |
-$46,000.00 |
-$26,000.00 |
$0.00 |
| Operating Expenses |
$1.70 M |
$173.73 M |
$166.65 M |
$168.39 M |
$144.87 M |
$41.48 M |
$25.11 M |
$15.59 M |
$8.20 M |
| Cost And Expenses |
$196.73 M |
$173.73 M |
$166.65 M |
$168.39 M |
$144.87 M |
$41.48 M |
$25.11 M |
$15.59 M |
$8.20 M |
| Interest Income |
$13.51 M |
$1.71 M |
$262,000.00 |
$536,000.00 |
$2.54 M |
$4.12 M |
$84,000.00 |
$75,000.00 |
$7,926.16 |
| Interest Expense |
$45.07 M |
$8.91 M |
$1.11 M |
$0.00 |
$0.00 |
$12,667.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$6.57 M
|
$7.42 M
|
$8.55 M
|
$5.75 M
|
$4.61 M
|
$1.71 M
|
$1.01 M
|
$478,000.00
|
$3.64 M
|
| EBITDA |
-$156.77 M
|
-$135.54 M
|
-$132.01 M
|
-$160.51 M
|
-$134.40 M
|
-$50.32 M
|
-$22.41 M
|
-$13.90 M
|
-$4.47 M
|
| EBITDA Ratio |
-92.33 |
-25.24 |
-66.85 |
-671.43 |
-45.82 |
-33.68 |
-13.24 |
-11.47 |
-47.5 |
| Operating Income Ratio
|
-114.86
|
-26.44
|
-70.48
|
-694.81
|
-47.41
|
-55.04
|
-13.83
|
-11.86
|
-86.14
|
| Total Other
Income/Expenses Net |
-$13.37 M
|
-$9.42 M
|
$109.23 M
|
$1.89 M
|
$2.95 M
|
$6.91 M
|
$38,000.00
|
$49,000.00
|
$7,926.00
|
| Income Before Tax |
-$208.40 M |
-$173.21 M |
-$165.99 M |
-$166.26 M |
-$139.01 M |
-$36.33 M |
-$23.38 M |
-$14.33 M |
-$8.10 M |
| Income Before Tax Ratio
|
-122.73
|
-27.96
|
-71.24
|
-687.01
|
-47.8
|
-34.75
|
-13.81
|
-11.82
|
-86.05
|
| Income Tax Expense |
-$19,000.00 |
-$24.37 M |
-$23.89 M |
-$24.16 M |
-$15.16 M |
-$5.21 M |
-$3.65 M |
-$1.78 M |
$634,507.00 |
| Net Income |
-$208.38 M |
-$148.84 M |
-$142.10 M |
-$142.09 M |
-$123.85 M |
-$31.11 M |
-$19.73 M |
-$12.55 M |
-$7.46 M |
| Net Income Ratio |
-122.72 |
-24.03 |
-60.99 |
-587.17 |
-42.59 |
-29.76 |
-11.65 |
-10.35 |
-79.31 |
| EPS |
-1.2 |
-1.57 |
-1.97 |
-2.76 |
-2.88 |
-0.99 |
-1.43 |
-0.91 |
-0.542 |
| EPS Diluted |
-1.2 |
-1.57 |
-1.97 |
-2.76 |
-2.88 |
-0.99 |
-1.43 |
-0.91 |
-0.542 |
| Weighted Average Shares
Out |
$173.94 M
|
$94.99 M
|
$72.08 M
|
$51.56 M
|
$43.07 M
|
$31.56 M
|
$13.78 M
|
$13.78 M
|
$13.78 M
|
| Weighted Average Shares
Out Diluted |
$173.94 M
|
$94.99 M
|
$72.08 M
|
$51.56 M
|
$43.07 M
|
$31.56 M
|
$13.78 M
|
$13.78 M
|
$13.78 M
|
| Link |
|
|
|
|
|
|
|
|
|
